Gemcitabine plus concurrent irreversible electroporation vs gemcitabine alone for locally advanced pancreatic cancer

Table 3 Univariate and multivariate analyses of overall survival in patients

Characteristic		GEM + IRE group (n = 33)			GEM group (n = 35)
		Univariate analysis			Multivariate analysis
		HR	95%CI	P value	HR	95%CI	P value
Age (yr)	≤ 60/> 60	1.632	0.763-3.325	0.121
Gender	Female/male	2.321	1.202-4.047	0.215
Tumor site	Head/body/tail	0.952	0.676-1.524	0.832
Tumor volume (cm3)	≤ 37/> 37	2.386	1.312-4.415	0.008	2.913	1.181-6.381	0.023
WBC (× 109)	≤ 10/> 10	1.128	0.343-2.872	0.988
HGB (g/L)	≤ 120/> 120	0.586	0.254-1.693	0.383
PLT (× 109)	≤ 300/> 300	1.218	0.526-2.867	0.672
ALT (U/L)	≤ 40/> 40	0.778	0.368-1.686	0.514
AST (U/L)	≤ 40/> 40	0.427	0.275-1.406	0.209
ALP (U/L)	≤ 100/> 100	0.895	0.506-1.824	0.793
CEA (ng/mL)	≤ 5/> 5	1.381	1.027-2.741	0.474
CA19-9 level	≤ 35/> 35	1.350	0.618-3.572	0.245
CA19-9 decrease 3 mo after treatment	≤ 50%/>50%	2.659	1.096-6.532	0.032	3.084	1.304-7.854	0.011
GEM	With/without IRE	0.389	0.178-0.952	0.045	0.422	0.157-0.958	0.047

IRE: Irreversible electroporation; GEM: Gemcitabine; HR: Hazard ratio; WBC: White blood cell count; HGB: Hemoglobin; PLT: Platelet count; ALT: Alanine transaminase; AST: Aspartate aminotransferase; ALP: Alkaline phosphatase; CEA: Carcinoembryonic antigen; CA19-9: Carbohydrate antigen 19-9.